Trial Profile
Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A.
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- 05 Nov 2014 New trial record
- 05 Nov 2014 New trial record
- 03 Nov 2014 Planned initiation date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.